Ford Motor Company (F) Races Forward in China

Page 1 of 2

Ford Motor Company (NYSE:F) has been spending big bucks to expand its lineup in China, and recent sales results suggest that Chinese consumers are liking what they’re seeing: The Blue Oval’s sales through the first two months of 2013 were up 46% over year-ago totals.

That’s huge. How huge? It trounced market leader General Motors Company (NYSE:GM)7.9% gain over the same two months – itself a good result for a period in which sales at rivals Toyota Motor Corporation (ADR) (NYSE:TM) and Honda Motor Co Ltd (ADR) (NYSE:HMC) actually declined.

More to the point, it’s proof that Ford’s product strategy is playing quite well in China – and that bodes very well for the Blue Oval’s ongoing expansion plans.

Ford Motor Company (NYSE:F)Big gains in a sluggish market
While most automakers report monthly sales results in the areas in which they do business, automakers doing business in China generally present their January and February results as a combined number. That’s because Chinese New Year, a week-long holiday celebration, sometimes falls in January (like in 2012) and sometimes in February (as it did this year) – making year-over-year monthly comparisons complicated.

But this year, despite losing a week of sales to the holiday, Ford Motor Company (NYSE:F)’s Chinese operation still posted a sales gain of 7% in February that looks even better when you dig into the details.

Ford Motor Company (NYSE:F) operates two separate joint ventures in China: Changan Ford Automobile, which produces familiar global Ford cars like the Focus, and a joint venture with Chinese truckmaker Jiangling Motors that produces Ford-branded commercial and government vehicles based on Ford’s Transit and E350 vans.

Of those two, Changan Ford Motor Company (NYSE:F) is the more significant operation, outselling the truck venture by more than two to one. And its sales have been rising sharply lately – up 39% in February alone — as Ford Motor Company (NYSE:F) brings more of its well-regarded global products to the Middle Kingdom.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!